Malignant Lymphoma Clinical Trial
Official title:
TEAM (Thiotepa, Etoposide, Cytosar, Melphalan ) in Preparation for Autologous Hematopoietic Stem-Cell Transplantation in Patients With Non-Hodgkin's and Hodgkin's Lymphoma.
Study is designed to explore whether the introduction of Thiotepa, to the pre autologous stem-cell transplantation (ASCT) conditioning will reduce toxicity and thus improve outcome following transplantation in up to 24 patients with malignant lymphoma including both non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma ( HL) improving toxicity profile , reducing side effects while potentially improving the antitumor response. Specifically,we speculate that using the novel Thiotepa based TEAM consisted of THIOTEPA 5mg/kg on days -7-6, etoposide 200 mg/m2 , Cytosar (ARA-C) 200 mg/m2 on days -5,-4, -3, -2 and melphalan 140 mg/m2 on day -1, pre transplantation conditioning regimen may allow transplantation with lower transplant related toxicity and thus improve outcome in this setting. Toward this aim the impact on toxicity profile ,engraftment and disease control will be assessed.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05190263 -
Quality Assurance on Anemia Management in Patients With Solid Tumors and Malignant Lymphoma
|
||
| Completed |
NCT01473095 -
Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma
|
Phase 1 | |
| Completed |
NCT00683046 -
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
|
Phase 2 | |
| Recruiting |
NCT02131688 -
Phase I Study of Mitoxantrone Hydrochloride Liposome Injection
|
Phase 1 | |
| Completed |
NCT00892502 -
Can Treatment With Bismuth Reduce Toxicity to Chemotherapy and Radiotherapy?
|
N/A | |
| Completed |
NCT00685997 -
Whole-body Magnetic Resonance Imaging (MRI) for Staging Malignant Lymphomas
|
N/A | |
| Not yet recruiting |
NCT06358001 -
EchoTip AcuCore Post-Market Clinical Study
|
||
| Recruiting |
NCT04986293 -
CPAP or BiPAP for Motion Mitigation During Radiotherapy
|
N/A | |
| Completed |
NCT01588548 -
Global Phase1 Study to Assess the Safety and Tolerability of AZD1208 in Advanced Solid Tumors and Malignant Lymphoma
|
Phase 1 | |
| Withdrawn |
NCT04464889 -
HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation
|
Phase 1 | |
| Completed |
NCT03316144 -
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma
|
Phase 1 | |
| Terminated |
NCT01016795 -
Stem Cell Factor (SCF) Priming of Haematopoietic Stem Cell Grafts in Malignant Lymphoma
|
Phase 2 | |
| Completed |
NCT04464590 -
Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT
|
||
| Recruiting |
NCT04698616 -
Lean Body Mass and Side Effects in Patients With Lymphoma
|
||
| Active, not recruiting |
NCT02678299 -
Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study
|
Phase 1/Phase 2 | |
| Completed |
NCT01499147 -
Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies
|
N/A | |
| Completed |
NCT01789060 -
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma
|
N/A | |
| Completed |
NCT05827341 -
A Real-World Study of COVID-19 Infection in Patients With Malignant Lymphomas Participating in Clinical Trials
|
||
| Active, not recruiting |
NCT05515029 -
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
|
Phase 3 | |
| Not yet recruiting |
NCT05545202 -
A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation
|
Phase 4 |